Drug
ARO-APOC3
ARO-APOC3 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
50%(2 trials)
Phase Distribution
Ph phase_2
3
75%
Ph phase_1
1
25%
Phase Distribution
1
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (25.0%)
Phase 23 (75.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia
NCT04998201
completedphase_2
Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia
NCT04720534
completedphase_1
Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)
NCT03783377
completedphase_2
Study of ARO-APOC3 in Adults With Dyslipidemia
NCT05413135
Clinical Trials (4)
Showing 4 of 4 trials
NCT04998201Phase 2
Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia
NCT04720534Phase 2
Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia
NCT03783377Phase 1
Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)
NCT05413135Phase 2
Study of ARO-APOC3 in Adults With Dyslipidemia
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4